iBio Inc IBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IBIO is a good fit for your portfolio.
News
-
Thinking about buying stock in Ibio, Village Farms International, MariaDB, Nexgel, or Urban Outfitters ?
-
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
-
iBio Announces $15.0 Million Private Placement
-
iBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka
-
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
-
Thinking about buying stock in Ibio Inc, Nokia, C4 Therapeutics, 1847 Holdings, or CleanSpark?
Trading Information
- Previous Close Price
- $1.90
- Day Range
- $1.83–1.98
- 52-Week Range
- $1.02–24.40
- Bid/Ask
- $1.85 / $1.90
- Market Cap
- $16.36 Mil
- Volume/Avg
- 99,189 / 4.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- 0.03
- Price/Sales
- 43.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.ibioinc.com
Valuation
|
Metric
|
IBIO
|
|---|---|
Price/Earnings (Normalized) | 0.03 |
Price/Book Value | 0.67 |
Price/Sales | 43.39 |
Price/Cash Flow | — |
Price/Earnings
IBIO
Financial Strength
|
Metric
|
IBIO
|
|---|---|
Quick Ratio | 0.13 |
Current Ratio | 0.91 |
Interest Coverage | −185.99 |
Quick Ratio
IBIO
Profitability
|
Metric
|
IBIO
|
|---|---|
Return on Assets (Normalized) | −35.83% |
Return on Equity (Normalized) | −101.23% |
Return on Invested Capital (Normalized) | −46.27% |
Return on Assets
IBIO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Srqzgyytd | Ysrjc | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xvvscskf | Fdgzkm | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fllygbk | Zhgvwg | $99.5 Bil | |
MRNA
| Moderna Inc | Pndxlqj | Ynpn | $38.8 Bil | |
ARGX
| argenx SE ADR | Xlgbjpf | Wvj | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Tbjtpvd | Hcjyj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dsspjtx | Cpggwd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vxzkfcr | Hzdsb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dkdytrcd | Vjnhc | $12.5 Bil | |
INCY
| Incyte Corp | Yqlwbwb | Pxgjj | $11.6 Bil |